Bioactive lipids as effectors and indicators of the deleterious effects of environmental exposure on chronic diseases

生物活性脂质作为环境暴露对慢性疾病有害影响的效应物和指标

基本信息

  • 批准号:
    10615675
  • 负责人:
  • 金额:
    $ 75.68万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-06-15 至 2027-04-30
  • 项目状态:
    未结题

项目摘要

Man’s total environment including diet, lifestyle and environmental chemicals has a major impact on health. The effects of environmental chemicals are most dramatic when they alter a regulatory system that amplifies the toxicity. We will examine effects of toxins and disease on lipid chemical mediators or oxylipins. Deleterious effects also are more global when the environmental chemicals alter a system fundamental to many cells and organs. Thus, we will investigate how environmental chemicals increase endoplasmic reticulum stress resulting in negative and often chronic outcomes in multiple organs. Natural epoxyfatty acids (EpFA) are a component of a regulatory system that maintains homeostasis. We are using inhibitors of the soluble epoxide hydrolase (sEHI) to stabilize these beneficial EpFA. A variety of environmental chemicals such as triclosan and nonsteroidal anti- inflammatory drugs damage these pathways enhancing disease states. sEHI restore the homeostatic systems leading to improvement in many disease models including for diabetes, heart failure, neuropathic and inflammatory pain, fibrosis and toxicities. Recently, we reported sEHI beneficial for treating cancer as well as Parkinson’s and depression. With the flexibility offered by the RIVER program, we will evaluate the relationships among these disease states, determine biochemical mechanisms, and monitor the levels of EpFA and other chemical mediators. Based on this knowledge we will develop cellular and biochemical biomarkers of health and disease particularly for diseases related to endoplasmic reticulum stress. We will continue providing the biochemical and analytical tools developed for this work for the broad scientific community. These tools include clones and proteins of the sEH enzyme, sEH inhibitors as probes and drugs, novel bioassays, antibodies and nanobodies, synthetic standards of regulatory lipids, and of course analytical methods. We will expand our testing of the hypothesis that toxicity and disease can be altered by pharmacological and nutritional intervention both in house and with collaborators. In particular, we will expand our recent studies that by stabilizing natural omega 6 and omega 3 fatty acid epoxides, sEHI can prevent and reverse symptoms of depression, Parkinson’s disease and other CNS disorders and block tumor resurgence and metastasis caused by cell debris from cancer chemotherapy and resection. Thus, we will test the hypothesis that the mitochondrial–ROS–ER stress axis is a common mechanism in the onset of many toxicities and pathological outcomes and that these effects can be prevented or reversed by increasing epoxyfatty acids. While carrying out the above research we continue and expand our work to reduce barriers to entering the oxylipin research field by providing service and reagents. Our research will be coupled with a training and outreach component to encourage collaboration and free information exchange in the oxylipin discipline. The work is transformative in emphasizing chronic rather than short-term toxicities, illustrating a new mechanism of toxicity in ER stress, and in exploring approaches to prevent the toxicities by manipulating endogenous chemical mediators.
人类的整体环境,包括饮食、生活方式和环境化学物质,对健康有重大影响。这 当环境化学物质改变了放大了环境影响的监管体系时,其影响最为显着。 毒性。我们将研究毒素和疾病对脂质化学介质或氧脂质的影响。有害影响 当环境化学物质改变许多细胞和器官的基本系统时,它也会变得更加全球化。 因此,我们将研究环境化学物质如何增加内质网应激,从而导致 多个器官的负面且通常是慢性的结果。天然环氧脂肪酸 (EpFA) 是 维持体内平衡的调节系统。我们正在使用可溶性环氧化物水解酶 (sEHI) 抑制剂 稳定这些有益的 EpFA。多种环境化学品,如三氯生和非甾体抗氧化剂 炎症药物会破坏这些通路,从而加剧疾病状态。 sEHI 恢复体内平衡系统 导致许多疾病模型的改善,包括糖尿病、心力衰竭、神经病和 炎性疼痛、纤维化和毒性。最近,我们报道了 sEHI 有益于治疗癌症以及 帕金森氏症和抑郁症。凭借 RIVER 计划提供的灵活性,我们将评估这些关系 在这些疾病状态中,确定生化机制,并监测 EpFA 和其他疾病的水平 化学介质。基于这些知识,我们将开发健康和健康的细胞和生化生物标志物。 疾病,特别是与内质网应激相关的疾病。我们将继续提供 为此工作为广大科学界开发的生化和分析工具。这些工具包括 sEH 酶的克隆和蛋白质、作为探针和药物的 sEH 抑制剂、新型生物测定法、抗体和 纳米抗体、监管脂质的合成标准,当然还有分析方法。我们将扩大我们的 检验药物和营养干预可以改变毒性和疾病的假设 无论是在内部还是与合作者。特别是,我们将扩展我们最近的研究,通过稳定自然 欧米伽 6 和欧米伽 3 脂肪酸环氧化物、sEHI 可以预防和逆转抑郁症、帕金森氏症的症状 疾病和其他中枢神经系统疾病,并阻止癌症细胞碎片引起的肿瘤复发和转移 化疗和切除。因此,我们将检验线粒体-ROS-ER 应激轴是一个假设 许多毒性和病理结果发生的共同机制,并且这些影响可以通过 通过增加环氧脂肪酸可以预防或逆转。在进行上述研究的同时,我们继续并 通过提供服务和试剂,扩大我们的工作,减少进入氧脂素研究领域的障碍。我们的 研究将与培训和外展相结合,以鼓励合作和免费信息 氧脂学科的交流。这项工作具有变革性,强调长期而非短期 毒性,阐明了 ER 应激中毒性的新机制,并探索了预防方法 通过操纵内源性化学介质来消除毒性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

BRUCE D HAMMOCK其他文献

BRUCE D HAMMOCK的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('BRUCE D HAMMOCK', 18)}}的其他基金

Soluble epoxide hydrolase and epoxide fatty acid involvement in corneal injury after ammonia exposure: Mechanisms of injury and potential therapeutics using sEH inhibitors and biostable EpFA mimics.
可溶性环氧化物水解酶和环氧化物脂肪酸参与氨暴露后角膜损伤:损伤机制和使用 sEH 抑制剂和生物稳定 EpFA 模拟物的潜在治疗方法。
  • 批准号:
    10708436
  • 财政年份:
    2023
  • 资助金额:
    $ 75.68万
  • 项目类别:
Bioactive lipids as effectors and indicators of the deleterious effects of environmental exposure on chronic diseases
生物活性脂质作为环境暴露对慢性疾病有害影响的效应物和指标
  • 批准号:
    10400036
  • 财政年份:
    2019
  • 资助金额:
    $ 75.68万
  • 项目类别:
Bioactive lipids as effectors and indicators of the deleterious effects of environmental exposure on chronic diseases
生物活性脂质作为环境暴露对慢性疾病有害影响的效应物和指标
  • 批准号:
    10153794
  • 财政年份:
    2019
  • 资助金额:
    $ 75.68万
  • 项目类别:
Clinical Paths for Soluble Epoxide Hydrolase Inhibitors at Experimental Biology 2018
2018 年实验生物学中可溶性环氧化物水解酶抑制剂的临床路径
  • 批准号:
    9544621
  • 财政年份:
    2018
  • 资助金额:
    $ 75.68万
  • 项目类别:
Role of Epoxygenated Fatty Acids in Modulating Pain
环氧化脂肪酸在调节疼痛中的作用
  • 批准号:
    8446055
  • 财政年份:
    2013
  • 资助金额:
    $ 75.68万
  • 项目类别:
Role of Epoxygenated Fatty Acids in Modulating Pain
环氧化脂肪酸在调节疼痛中的作用
  • 批准号:
    8619587
  • 财政年份:
    2013
  • 资助金额:
    $ 75.68万
  • 项目类别:
Analytical Chemistry
分析化学
  • 批准号:
    10204120
  • 财政年份:
    2012
  • 资助金额:
    $ 75.68万
  • 项目类别:
METHODS MONITOR TOXIC SUBSTAN AND/OR INDICATORS OF PRESENCE IN HUMANS&OTHER SPE
监测人类体内有毒物质和/或存在指标的方法
  • 批准号:
    8362756
  • 财政年份:
    2011
  • 资助金额:
    $ 75.68万
  • 项目类别:
EFFECT OF PHTHALATES ON PRIMATE PREGNANCY
邻苯二甲酸盐对灵长类动物怀孕的影响
  • 批准号:
    8357275
  • 财政年份:
    2011
  • 资助金额:
    $ 75.68万
  • 项目类别:
ID AND DEV OF BIOLOGICAL MARKERS OF HUMAN EXPOSURE TO THE INSECTICIDE PERMETHRI
人类接触杀虫剂氯菊酯的生物标志物的识别和开发
  • 批准号:
    8362754
  • 财政年份:
    2011
  • 资助金额:
    $ 75.68万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 75.68万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 75.68万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 75.68万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 75.68万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 75.68万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 75.68万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 75.68万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 75.68万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 75.68万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 75.68万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了